Recently, the inhibitors of EYA2, a member of a class of protein tyrosine phosphatases, have been experimentally investigated.43, 44 Therefore, miR-338-3p activation or EYA2 inhibition or combination therapy targeting EGFR/miR-338-3p/EYA2 axis may be a promising way to treat patients with metastatic cancer. The gene discussed is EYA2; the disease is metastatic malignant neoplasm.